Fibroid Embolisation: Information, Support, AdviceFEmISA was set up by women whose fibroids were successfully treated by embolisation (sometimes referred to as UAE or UFE). Many of us were keen to avoid hysterectomy and we want to ensure that other women have access to embolisation for the treatment of uterine fibroids by: -
FEmISA is a UK based not-for-profit organisation. It is run by volunteers and funded by group members. FEmISA does not receive any financial support through advertising, nor benefit from free website hosting or similar sponsorship. This web site contains information for women and for the medical profession. Twitter - @FEmISA_fibroids This web site is sponsored by Medical Marketing Consultants Ltd. a specialist medical and healthcare strategic business and marketing consultancy for all medical and healthcare sectors. Disclaimer - FEmISA has provided this informative as guidance only; the author is not a medical doctor. Whilst we have researched it thoroughly we cannot accept any responsibility for its accuracy. It does not take the place of a consultation with your doctor. All women are advised to discuss the most appropriate treatment options for them with their GP, interventional radiologist and gynaecologist. |
You are here:
Our Survey and Guidelines
NICE Review of their Clinical Guidlines on Heavy Menstrual Bleeding carried out by part of RCOG is launched 14th March'18. FEmISA condemns it as unsafe for women - see our press release. FEmISA queries NICE's figures on hysteroscopy. This is regressive - see our concerns and our submission to this NICE eEview.
See FEmISA's new report on NICE compliance and patient choice for fibroid treatments part of this report was included in the recent APPG On Women's Health report Informed Choice? Giving women control of their healthcare
Thanks to all who took part in our survey about the information and choices for their fibroid treatment. Please click here for the Patient Information and Choice Survey report and here for our report on access to UFE treatment with The Medical Technology Group and All Party Parliamentary Group on Improving Patient Access to Medical Technologies.